JACC. Heart failure, 2213-1779


  1. 2020
  2. 2019
  3. PARAGON-HF Investigators, Chandra, A., Vaduganathan, M., Lewis, E. F., Claggett, B. L., Rizkala, A. R., ... Solomon, S. D. (2019). Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction The PARAGON-HF Trial. JACC. Heart failure, 7(10), 862-874. https://doi.org/10.1016/j.jchf.2019.05.015
  4. GENETIC-AF Trial Investigators, Piccini, J. P., Abraham, W. T., Dufton, C., Carroll, I. A., Healey, J. S., ... Connolly, S. J. (2019). Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial. JACC. Heart failure, 7(7), 586-598. https://doi.org/10.1016/j.jchf.2019.04.004
  5. Wolsk, E., Kaye, D., Komtebedde, J., Shah, S. J., Borlaug, B. A., Burkhoff, D., ... Gustafsson, F. (2019). Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction. JACC. Heart failure, 7(4), 321-332. https://doi.org/10.1016/j.jchf.2019.01.006
  6. Savarese, G., Vedin, O., D'Amario, D., Uijl, A., Dahlstrom, U., Rosano, G., ... Lund, L. H. (2019). Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure. JACC. Heart failure, 7(4), 306-317. https://doi.org/10.1016/j.jchf.2018.11.019
  7. Beldhuis, I. E., Myhre, P. L., Claggett, B., Damman, K., Fang, J. C., Lewis, E. F., ... Desai, A. S. (2019). Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease. JACC. Heart failure, 7(1), 25-32. https://doi.org/10.1016/j.jchf.2018.10.017
  8. 2018
  9. Damman, K., Gori, M., Claggett, B., Jhund, P. S., Senni, M., Lefkowitz, M. P., ... McMurray, J. J. V. (2018). Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC. Heart failure, 6(6), 489-498. https://doi.org/10.1016/j.jchf.2018.02.004
  10. Cerbin, L. P., Ambrosy, A. P., Greene, S. J., Armstrong, P. W., Butler, J., Coles, A., ... Mentz, R. J. (2018). Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial. JACC. Heart failure, 6(4), 298-307. https://doi.org/10.1016/j.jchf.2018.01.018
  11. 2017
  12. Aimo, A., Vergaro, G., Ripoli, A., Bayes-Genis, A., Pascual Figal, D. A., de Boer, R. A., ... Emdin, M. (2017). Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure. JACC. Heart failure, 5(4), 287-296. https://doi.org/10.1016/j.jchf.2016.12.016
  13. 2016
  14. Zipes, D. P., Neuzil, P., Theres, H., Caraway, D., Mann, D. L., Mannheimer, C., ... DEFEAT-HF Trial Investigators (2016). Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure The DEFEAT-HF Study. JACC. Heart failure, 4(2), 129-136. https://doi.org/10.1016/j.jchf.2015.10.006
  15. 2015
  16. Davison, B. A., Metra, M., Cotter, G., Massie, B. M., Cleland, J. G. F., Dittrich, H. C., ... PROTECT & RELAX-AHF Executive Comm (2015). Worsening Heart Failure Following Admission for Acute Heart Failure A Pooled Analysis of the PROTECT and RELAX-AHF Studies. JACC. Heart failure, 3(5), 395-403. https://doi.org/10.1016/j.jchf.2015.01.007
  17. 2013

ID: 14240803